Moderna mRNA-1273 vaccine, developed for COVID-19, yielded 94.5% efficacy in early results of the phase 3 COVE trial. 90 who were COVID-19 pos were in a placebo group and that 5 patients were in the mRNA-1273 vaccine group. https://t.co/9245wj3kph